Ankit Mahadevia, M.D.

Ankit Mahadevia, M.D.

DirectoratSpero Therapeutics· In proxies 2022–2025

Pay in FY2023-44% from the year before · Spero Therapeutics stock -15.0% the same year

Ankit Mahadevia, M.D. was paid $2.4M in FY2023 (Dec), down 44%. Spero Therapeutics stock fell 15.0% that year.

Pay$100 in the stock at the end of FY21 → $9
Pay is from the Summary Compensation Table of each Spero Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Spero TherapeuticsPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role -92%
  2. Judo BioPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?